MIRNA THERAPEUTICS, INC.

Basic Information

2150 WOODWARD ST
AUSTIN, TX, 78744-1038

Company Profile

n/a

Additional Details

Field Value
DUNS: 805509424
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease

    Amount: $224,996.00

    DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. There is a clear need for more effective therapies to treat deadly panc ...

    STTR Phase I 2014 Department of Health and Human Services
  2. Systemic delivery of chitosan/miRNA nanoparticles to prostate tumors

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have emerged as a promising new class of therapeutics for cancer. miRNAs are small, non-coding RNAs that determine cell fate by post-transcripti ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Therapeutic miRNAs in combination with conventional chemotherapy

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replace ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. MicroRNA therapeutics for prostate cancer

    Amount: $282,967.00

    DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths in males, following only lung cancer. Despite adv ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Development of modified microRNA therapeutics

    Amount: $287,270.00

    DESCRIPTION (provided by applicant): Experimental evidence accumulated in the past few years indicates that several miRNAs likely function as tumor suppressors and that the altered expression of these ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Combination molecular therapeutics for lung cancer

    Amount: $171,527.00

    DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the United States with an estimated gt160,000 deaths and gt200,000 newly diagnosed cases each year. Despite th ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government